IMPLEMENTATION LEVEL

National

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

all

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: No inception date

Production subsidy

Decree No. 1045 regulates the procedure for allocation of subsidies from the federal budget of the Russian Federation to Russian organisation. Their purpose is to compensate part of the expenses for clinical trials of medical products as part of the framework of the state programme for the development of the pharmaceutical and medical production in the period 2013--2020.

The state subsidies under Decree No. 1045 are provided for the development of the innovative potential of the pharmaceutical industry in accordance with the priority directions of scientific research. The priority medicines that are subsidised under Decree No. 1045 are indicated in its article 3. They are for the treatment of cancer, autoimmune and neurodegenerative diseases, endocrine diseases, diabetes, cardiovascular diseases, infectious diseases, tuberculosis, HIV-infection and viral hepatitis.

The maximum subsidy may not exceed 200 million Russian Roubles (3.04 million USD) for the whole term of validity of a contract. An eligible beneficiary may receive a subsidy not more often than twice per year. Costs incurred not earlier than 1 January 2015 in the amount of not more than 50% of the cost for acquisition of raw materials, consumables, services of external organisations for research and transportation of clinical samples, etc. are eligible. 

The provided official note that accompanies Decree No. 1045 states that it (together with other indicated as related state acts by the GTA) "will contribute to import substitution in the pharmaceutical and medical industries, will enhance the investment activity of the Russian organisations with the goal to create and modernise the production, will increase the share of domestically produced medicines and medical products, will create high-performance workplaces."

The GTA includes state guarantees and other financial incentives that are likely to affect the restructuring and performance of firms facing international competition, whether from imports, in export markets and from foreign subsidiaries.

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

352 Pharmaceutical products
2937 Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis; derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones.
293712 Insulin and its salts
3003 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.
300310 Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives
300320 Containing other antibiotics
300331 Containing insulin
300390 Other
3004 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packin
300410 Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives
300420 Containing other antibiotics
300431 Containing insulin
300432 Containing corticosteroid hormones, their derivatives or structural analogues
300439 Other
300440 Containing alkaloids or derivatives thereof but not containing hormones, other products of heading 29.37 or antibiotics
300450 Other medicaments containing vitamins or other products of heading 29.36
300490 Other

Please report this page in case you detect an inaccuracy in its content.